Literature DB >> 25518860

A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.

T Justin Rettenmaier1, Jack D Sadowsky2, Nathan D Thomsen2, Steven C Chen3, Allison K Doak2, Michelle R Arkin3, James A Wells4.   

Abstract

There is great interest in developing selective protein kinase inhibitors by targeting allosteric sites, but these sites often involve protein-protein or protein-peptide interfaces that are very challenging to target with small molecules. Here we present a systematic approach to targeting a functionally conserved allosteric site on the protein kinase PDK1 called the PDK1-interacting fragment (PIF)tide-binding site, or PIF pocket. More than two dozen prosurvival and progrowth kinases dock a conserved peptide tail into this binding site, which recruits them to PDK1 to become activated. Using a site-directed chemical screen, we identified and chemically optimized ligand-efficient, selective, and cell-penetrant small molecules (molecular weight ∼ 380 Da) that compete with the peptide docking motif for binding to PDK1. We solved the first high-resolution structure of a peptide docking motif (PIFtide) bound to PDK1 and mapped binding energy hot spots using mutational analysis. We then solved structures of PDK1 bound to the allosteric small molecules, which revealed a binding mode that remarkably mimics three of five hot-spot residues in PIFtide. These allosteric small molecules are substrate-selective PDK1 inhibitors when used as single agents, but when combined with an ATP-competitive inhibitor, they completely suppress the activation of the downstream kinases. This work provides a promising new scaffold for the development of high-affinity PIF pocket ligands, which may be used to enhance the anticancer activity of existing PDK1 inhibitors. Moreover, our results provide further impetus for exploring the helix αC patches of other protein kinases as potential therapeutic targets even though they involve protein-protein interfaces.

Entities:  

Keywords:  allostery; drug discovery; peptide mimicry; protein–protein interaction

Mesh:

Substances:

Year:  2014        PMID: 25518860      PMCID: PMC4284534          DOI: 10.1073/pnas.1415365112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

Review 1.  Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist.

Authors:  Kevin Beaumont; Robert Webster; Iain Gardner; Kevin Dack
Journal:  Curr Drug Metab       Date:  2003-12       Impact factor: 3.731

2.  A specific mechanism of nonspecific inhibition.

Authors:  Susan L McGovern; Brian T Helfand; Brian Feng; Brian K Shoichet
Journal:  J Med Chem       Date:  2003-09-25       Impact factor: 7.446

3.  A hot spot of binding energy in a hormone-receptor interface.

Authors:  T Clackson; J A Wells
Journal:  Science       Date:  1995-01-20       Impact factor: 47.728

4.  Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP.

Authors:  Jing Yang; Peter Cron; Valerie M Good; Vivienne Thompson; Brian A Hemmings; David Barford
Journal:  Nat Struct Biol       Date:  2002-12

5.  Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA.

Authors:  R M Biondi; P C Cheung; A Casamayor; M Deak; R A Currie; D R Alessi
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

6.  High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site.

Authors:  Ricardo M Biondi; David Komander; Christine C Thomas; Jose M Lizcano; Maria Deak; Dario R Alessi; Daan M F van Aalten
Journal:  EMBO J       Date:  2002-08-15       Impact factor: 11.598

7.  Evaluation of fluorescent compound interference in 4 fluorescence polarization assays: 2 kinases, 1 protease, and 1 phosphatase.

Authors:  Tammy C Turek-Etienne; Eliza C Small; Sharon C Soh; Tianpei A Xin; Priti V Gaitonde; Ellen B Barrabee; Richard F Hart; Robert W Bryant
Journal:  J Biomol Screen       Date:  2003-04

8.  Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization.

Authors:  Zaneta Nikolovska-Coleska; Renxiao Wang; Xueliang Fang; Hongguang Pan; York Tomita; Peng Li; Peter P Roller; Krzysztof Krajewski; Naoyuki G Saito; Jeanne A Stuckey; Shaomeng Wang
Journal:  Anal Biochem       Date:  2004-09-15       Impact factor: 3.365

9.  Selective 3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: dissecting the function and pharmacology of PDK1.

Authors:  Jesús R Medina
Journal:  J Med Chem       Date:  2013-03-15       Impact factor: 7.446

10.  In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation.

Authors:  Barry J Collins; Maria Deak; J Simon C Arthur; Laura J Armit; Dario R Alessi
Journal:  EMBO J       Date:  2003-08-15       Impact factor: 11.598

View more
  28 in total

1.  Allosteric modulation of a human protein kinase with monobodies.

Authors:  Adelajda Zorba; Vy Nguyen; Akiko Koide; Marc Hoemberger; Yuejiao Zheng; Steffen Kutter; Chansik Kim; Shohei Koide; Dorothee Kern
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-25       Impact factor: 11.205

Review 2.  Non-kinase targets of protein kinase inhibitors.

Authors:  Lenka Munoz
Journal:  Nat Rev Drug Discov       Date:  2017-03-10       Impact factor: 84.694

3.  A tripartite cooperative mechanism confers resistance of the protein kinase A catalytic subunit to dephosphorylation.

Authors:  Tung O Chan; Roger S Armen; Santosh Yadav; Sushrut Shah; Jin Zhang; Brian C Tiegs; Nikhil Keny; Brian Blumhof; Deepak A Deshpande; Ulrich Rodeck; Raymond B Penn
Journal:  J Biol Chem       Date:  2020-01-21       Impact factor: 5.157

4.  Rational Design of Selective Adenine-Based Scaffolds for Inactivation of Bacterial Histidine Kinases.

Authors:  Manibarsha Goswami; Kaelyn E Wilke; Erin E Carlson
Journal:  J Med Chem       Date:  2017-10-03       Impact factor: 7.446

Review 5.  Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases.

Authors:  Christine Yueh; Justin Rettenmaier; Bing Xia; David R Hall; Andrey Alekseenko; Kathryn A Porter; Krister Barkovich; Gyorgy Keseru; Adrian Whitty; James A Wells; Sandor Vajda; Dima Kozakov
Journal:  J Med Chem       Date:  2019-07-05       Impact factor: 7.446

6.  Discovery of a Potent Allosteric Kinase Modulator by Combining Computational and Synthetic Methods.

Authors:  Edwin Kroon; Jörg O Schulze; Evelyn Süß; Carlos J Camacho; Ricardo M Biondi; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2015-09-04       Impact factor: 15.336

7.  Akt Kinase Activation Mechanisms Revealed Using Protein Semisynthesis.

Authors:  Nam Chu; Antonieta L Salguero; Albert Z Liu; Zan Chen; Daniel R Dempsey; Scott B Ficarro; William M Alexander; Jarrod A Marto; Yana Li; L Mario Amzel; Sandra B Gabelli; Philip A Cole
Journal:  Cell       Date:  2018-08-02       Impact factor: 41.582

8.  Atypical activation of the G protein Gαq by the oncogenic mutation Q209P.

Authors:  Marcin Maziarz; Anthony Leyme; Arthur Marivin; Alex Luebbers; Prachi P Patel; Zhe Chen; Stephen R Sprang; Mikel Garcia-Marcos
Journal:  J Biol Chem       Date:  2018-10-23       Impact factor: 5.157

9.  Small-Molecule Allosteric Modulators of the Protein Kinase PDK1 from Structure-Based Docking.

Authors:  T Justin Rettenmaier; Hao Fan; Joel Karpiak; Allison Doak; Andrej Sali; Brian K Shoichet; James A Wells
Journal:  J Med Chem       Date:  2015-10-12       Impact factor: 7.446

10.  A peptide of the RGS domain of GRK2 binds and inhibits Gα(q) to suppress pathological cardiac hypertrophy and dysfunction.

Authors:  Sarah M Schumacher; Erhe Gao; Maya Cohen; Melissa Lieu; J Kurt Chuprun; Walter J Koch
Journal:  Sci Signal       Date:  2016-03-22       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.